Bridging the Gaps in Lung Cancer: 6 Month Update Winter Lung Cancer Conference 2025 - Episode 3
Expert Perspectives on Tarlatamab in ES-SCLC
Panelists discuss how the DeLLphi-301 trial demonstrated that tarlatamab, administered biweekly at a 10 mg dose, achieved a 40% objective response rate in patients with previously treated extensive-stage small cell lung cancer (ES-SCLC). This led to its accelerated FDA approval in May 2024. Integrating tarlatamab into clinical practice may present challenges, including managing cytokine release syndrome and neurologic toxicities, as well as addressing financial considerations.
Video content above is prompted by the following:
- What are your thoughts on the latest data from DeLLphi-301 trial and the recent approval of tarlatamab in this setting?
- How do intracranial efficacy data demonstrated with tarlatamab influence your treatment approach in patients with ES-SCLC and central nervous system involvement?
- What are the key barriers to incorporating tarlatamab into your clinical practice (resources, educational needs, finances, etc)?
Related Content:
